A. Pinta

Two-Year Observational Study in Patients Infected with Drug-Resistant HIV-1 and Treated with the Fusion Inhibitor Enfuvirtide: The ZOOM Cohort

G. Chêne, P. Girard, J. Meynard, 2011 .

Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.

V. de Lédinghen, D. Sautereau, P. Marquet, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

V. Cottin, E. Clay, O. Cristeau, 2019, Journal of market access & health policy.

Lack of benefit of 3‐month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: The INNOVE study

A. Samri, C. Delaugerre, F. Raffi, 2012, Journal of medical virology.

Pegylated Interferon-α2A plus Ribavirin for Chronic Hepatitis C in a Real-Life Setting: The Hepatys French Cohort (2003–2007)

P. Marcellin, J. Pawlotsky, D. Ouzan, 2012, Antiviral therapy.

Non‐invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study

M. Chevallier, P. Sogni, J. Zarski, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Pegylated Interferon-α2A plus Ribavirin for Chronic Hepatitis C in a Real-Life Setting: The Hepatys French Cohort (2003–2007)

P. Marcellin, J. Pawlotsky, D. Ouzan, 2012, Antiviral therapy.